U.S. markets closed

INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation of CytomX Therapeutics, Inc. (CTMX) on Behalf of Investors

Law Offices of Howard G. Smith announces an investigation on behalf of CytomX Therapeutics, Inc. ("CytomX" or the "Company") (NASDAQ: CTMX) investors concerning the Company and its officers’ possible violations of federal securities laws.

On May 13, 2020, the Company made available abstracts for the Company’s clinical presentations for CX-072 and CX-2009. Results from the PROCLAIM-CX-072 clinical program revealed a response rate of 8.8%, compared to a response rate of 18.5% in patients receiving the combination of CX-072 and ipilimumab. Meanwhile, results from the PROCLAIM-CX-2009 clinical program showed "evidence" of clinical activity at doses at least 4 mg/kg 3x/week, but also suggested a significantly higher rate of serious or greater treatment-related toxicity to the eyes at dose equivalents at least 8 mg/kg 3x/week.

On this news, the Company’s share price fell $5.21 per share, or over 36%, to close at $9.23 per share on May 14, 2020, thereby injuring investors.

If you purchased CytomX securitites, have information or would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Howard G. Smith, Esquire, of Law Offices of Howard G. Smith, 3070 Bristol Pike, Suite 112, Bensalem, Pennsylvania 19020 by telephone at (215) 638-4847, toll-free at (888) 638-4847, or by email to howardsmith@howardsmithlaw.com, or visit our website at www.howardsmithlaw.com.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

View source version on businesswire.com: https://www.businesswire.com/news/home/20200526005826/en/


Law Offices of Howard G. Smith
Howard G. Smith, Esquire